Skip to content
Head to head

ANI Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: ANIP · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

ANIP -16.4%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
ANIPTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price68.5521.77
Change today-0.84%+1.68%
1-year return-12.7%+57.5%
Market cap$1.56B$69.76B
52-week range67.14 – 87.7613.92 – 22.07
Valuation
P/E (TTM)13.63311.00
P/E percentile, own 5-yr range60th100th
P/B2.441.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)3.32-0.30
Net profit (TTM)$75.43M$-970.94M
Revenue (TTM)$1.04B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+27.6%+6.7%
Gross margin61.1%65.8%
Operating margin15.3%14.3%
Net margin10.6%0.9%
Free cash flow (TTM)$199.91M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership122.3%51.3%
Insider activity (12mo)6 buy / 44 sell19 buy / 31 sell
Short interest (% of float)15.6%0.1%
Analyst consensus71% buy / 29% hold (7)100% buy (1)
Analyst price target$105 (+53%)$50 (+132%)
StockVane view
StockVane Quant RatingD (24)C (90)
Company
Employees97047,029
Founded19961781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.